23 Nov 2006
BioMS Medical announced that the first patients have been enrolled in its placebo controlled multi-center Phase II clinical trial of MBP8298 for the treatment of relapsing remitting multiple sclerosis (RRMS).
EDMONTON, Canada | Nov 23, 2006 | BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the first patients have been enrolled in its placebo controlled multi-center Phase II clinical trial of MBP8298 for the treatment of relapsing remitting multiple sclerosis (RRMS).
"This is a major milestone in our strategy to advance our lead drug into a second indication," said Mr. Kevin Giese, President of BioMS Medical.
"MBP8298 has shown potential to significantly delay disease progression in secondary progressive MS (SPMS) patients with immune response genes HLA-DR2 and/or DR4 and we look forward to evaluating the potential efficacy of our lead drug in RRMS patients, who represent an equally large patient population."
The fifteen month, double-blind, placebo-controlled trial will enroll up to 215 patients with RRMS from up to 30 sites. The trial will be followed by a 12 month active treatment open label extension period. The objectives of the study are to demonstrate safety and efficacy of MBP8298 versus placebo as measured by relapse rate, MRI activity and disease progression.
RRMS and SPMS each affect 40 - 45% of the estimated 2.5 million MS patients worldwide. Patients with the immune response genes, HLA-DR2 or HLA-DR4, account for up to 75% of the MS patient population.
MBP8298 is also currently undergoing a pivotal phase III trial for the treatment of secondary progressive multiple sclerosis (SPMS), with interim data from this trial anticipated in approximately 18 months.
About BioMS Medical Corp.
BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, MBP8298, is for the treatment of multiple sclerosis and is currently in a pivotal Phase II/III clinical trial across Canada and Europe.
For further information please visit our website at www.biomsmedical.com.
This news release may contain certain forward-looking statements that reflect the current views and/or expectations of BioMS Medical with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.
For further information: Tony Hesby, Ryan Giese, Corporate Communications, BioMS Medical Corp., (780) 413-7152, (780) 408-3040 Fax, E-mail: rgiese@biomsmedical.com, Internet: www.biomsmedical.com; James Smith,
Investor Relations, (416) 815-0700 ext. 229, (416) 815-0080 Fax, E-mail: jsmith@equicomgroup.com; Mr. Barry Mire, Investor Relations, Quebec, Phone: (514) 939-3989, E-mail: bmire@renmarkfinancial.com
SOURCE: BioMS Medical Corp
